• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

分析鼠疫耶尔森菌V蛋白中线性抗体表位的存在情况。

Analysis of the Yersinia pestis V protein for the presence of linear antibody epitopes.

作者信息

Pullen J K, Anderson G W, Welkos S L, Friedlander A M

机构信息

Bacteriology Division, U.S. Army Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland 21702-5011, USA.

出版信息

Infect Immun. 1998 Feb;66(2):521-7. doi: 10.1128/IAI.66.2.521-527.1998.

DOI:10.1128/IAI.66.2.521-527.1998
PMID:9453605
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC107937/
Abstract

The V protein expressed by pathogenic Yersinia pestis is an important virulence factor and protective immunogen. The presence of linear B-cell epitopes in the V protein was investigated by using a series of 17 overlapping linear peptides. Groups of 10 mice were immunized intraperitoneally with 30 microg of each peptide on days 0, 30, and 60. Although the V protein-specific antibody response to the peptides varied, most of the peptides elicited high antibody titers. The immunized mice were challenged subcutaneously with 60 50% lethal doses (LD50) (1 LD50 = 1.9 CFU) of a virulent Y. pestis strain, CO92. None of the peptide-immunized mice survived challenge. The animals immunized with the V protein were completely protected against challenge. The immunogenicity of some of the V peptides was increased by conjugating them to keyhole limpet hemocyanin. Only one peptide (encompassing amino acids 1 to 30) conjugate demonstrated some protection; the others were not protective. In additional experiments, V peptides that reacted well with sera from mice surviving Y. pestis infection were combined and used to immunize mice. Although the combined peptides appeared to be very immunogenic, they were not protective. Therefore, the protective B-lymphocyte epitope(s) in the V protein is most likely to be conformational.

摘要

致病性鼠疫耶尔森菌表达的V蛋白是一种重要的毒力因子和保护性免疫原。利用一系列17种重叠线性肽研究了V蛋白中线性B细胞表位的存在情况。在第0、30和60天,每组10只小鼠腹腔注射30微克每种肽。虽然对这些肽的V蛋白特异性抗体反应各不相同,但大多数肽都能诱导出高抗体滴度。用60个50%致死剂量(LD50)(1个LD50 = 1.9 CFU)的强毒鼠疫耶尔森菌菌株CO92对免疫小鼠进行皮下攻击。肽免疫的小鼠在攻击后均未存活。用V蛋白免疫的动物对攻击具有完全保护作用。将一些V肽与钥孔戚血蓝蛋白偶联后,其免疫原性增强。只有一种肽(包含氨基酸1至30)偶联物表现出一定的保护作用;其他偶联物则没有保护作用。在另外的实验中,将与鼠疫耶尔森菌感染存活小鼠血清反应良好的V肽组合起来用于免疫小鼠。虽然组合肽似乎具有很强的免疫原性,但它们没有保护作用。因此,V蛋白中的保护性B淋巴细胞表位很可能是构象性的。

相似文献

1
Analysis of the Yersinia pestis V protein for the presence of linear antibody epitopes.分析鼠疫耶尔森菌V蛋白中线性抗体表位的存在情况。
Infect Immun. 1998 Feb;66(2):521-7. doi: 10.1128/IAI.66.2.521-527.1998.
2
Identifying B and T cell epitopes and studying humoral, mucosal and cellular immune responses of peptides derived from V antigen of Yersinia pestis.鉴定鼠疫耶尔森菌V抗原衍生肽的B细胞和T细胞表位,并研究其体液免疫、黏膜免疫和细胞免疫反应。
Vaccine. 2008 Jan 17;26(3):316-32. doi: 10.1016/j.vaccine.2007.11.028. Epub 2007 Dec 3.
3
Regions of Yersinia pestis V antigen that contribute to protection against plague identified by passive and active immunization.通过被动和主动免疫鉴定出的鼠疫耶尔森菌V抗原中有助于预防鼠疫的区域。
Infect Immun. 1997 Nov;65(11):4476-82. doi: 10.1128/iai.65.11.4476-4482.1997.
4
Yersinia pestis V protein epitopes recognized by CD4 T cells.被CD4 T细胞识别的鼠疫耶尔森菌V蛋白表位
Infect Immun. 2005 Apr;73(4):2197-204. doi: 10.1128/IAI.73.4.2197-2204.2005.
5
Evaluation of protective potential of Yersinia pestis outer membrane protein antigens as possible candidates for a new-generation recombinant plague vaccine.评估鼠疫耶尔森菌外膜蛋白抗原作为新一代重组鼠疫疫苗潜在候选物的保护潜力。
Clin Vaccine Immunol. 2013 Feb;20(2):227-38. doi: 10.1128/CVI.00597-12. Epub 2012 Dec 12.
6
Humoral immune responses and protective efficacy of sequential B- and T-cell epitopes of V antigen of Yersinia pestis by intranasal immunization in microparticles.经鼻免疫微颗粒中鼠疫耶尔森菌 V 抗原 B 和 T 细胞表位顺序诱导的体液免疫应答和保护效力。
Med Microbiol Immunol. 2009 Nov;198(4):247-56. doi: 10.1007/s00430-009-0124-7. Epub 2009 Sep 25.
7
Induction of Protective Antiplague Immune Responses by Self-Adjuvanting Bionanoparticles Derived from Engineered Yersinia pestis.工程化鼠疫耶尔森菌衍生的自佐剂化生物纳米颗粒诱导保护性抗鼠疫免疫应答。
Infect Immun. 2020 Apr 20;88(5). doi: 10.1128/IAI.00081-20.
8
Intramuscular Immunization of Mice with a Live-Attenuated Triple Mutant of Yersinia pestis CO92 Induces Robust Humoral and Cell-Mediated Immunity To Completely Protect Animals against Pneumonic Plague.用鼠疫耶尔森菌CO92的减毒活三重突变体对小鼠进行肌肉注射免疫可诱导强大的体液免疫和细胞介导免疫,从而完全保护动物免受肺鼠疫感染。
Clin Vaccine Immunol. 2015 Dec;22(12):1255-68. doi: 10.1128/CVI.00499-15. Epub 2015 Oct 7.
9
Complete Protection against Pneumonic and Bubonic Plague after a Single Oral Vaccination.单次口服疫苗接种后对肺鼠疫和腺鼠疫的完全防护
PLoS Negl Trop Dis. 2015 Oct 16;9(10):e0004162. doi: 10.1371/journal.pntd.0004162. eCollection 2015.
10
Human anti-plague monoclonal antibodies protect mice from Yersinia pestis in a bubonic plague model.人源抗鼠疫单克隆抗体在腺鼠疫模型中保护小鼠免受鼠疫耶尔森菌感染。
PLoS One. 2010 Oct 13;5(10):e13047. doi: 10.1371/journal.pone.0013047.

引用本文的文献

1
The Natural and Clinical History of Plague: From the Ancient Pandemics to Modern Insights.鼠疫的自然史与临床史:从古代大流行到现代认知
Microorganisms. 2024 Jan 11;12(1):146. doi: 10.3390/microorganisms12010146.
2
Metallacarborane Derivatives Effective against and .金属卡宾硼烷衍生物有效对抗 和 。
Int J Mol Sci. 2021 Jun 23;22(13):6762. doi: 10.3390/ijms22136762.
3
Antigen F1 but Not LcrV Induced Humoral and Cellular Immune Responses in Humans Immunized with Live Plague Vaccine-Comparison of Immunoinformatic and Immunological Approaches.抗原F1而非LcrV在接种活鼠疫疫苗的人体中诱导体液免疫和细胞免疫反应——免疫信息学与免疫学方法的比较
Vaccines (Basel). 2020 Nov 19;8(4):698. doi: 10.3390/vaccines8040698.
4
Benchmarking B-cell epitope prediction with quantitative dose-response data on antipeptide antibodies: towards novel pharmaceutical product development.利用抗肽抗体的定量剂量反应数据对B细胞表位预测进行基准测试:迈向新型药品开发
Biomed Res Int. 2014;2014:867905. doi: 10.1155/2014/867905. Epub 2014 May 11.
5
A systems approach to designing next generation vaccines: combining α-galactose modified antigens with nanoparticle platforms.一种设计下一代疫苗的系统方法:将α-半乳糖修饰抗原与纳米颗粒平台相结合。
Sci Rep. 2014 Jan 20;4:3775. doi: 10.1038/srep03775.
6
Purification and characterization of Yersinia enterocolitica and Yersinia pestis LcrV-cholera toxin A(2)/B chimeras.小肠结肠炎耶尔森菌和鼠疫耶尔森菌LcrV-霍乱毒素A(2)/B嵌合体的纯化与鉴定
Protein Expr Purif. 2010 Nov;74(1):16-23. doi: 10.1016/j.pep.2010.04.021. Epub 2010 May 11.
7
Amino acid and structural variability of Yersinia pestis LcrV protein.鼠疫耶尔森氏菌 LcrV 蛋白的氨基酸和结构变异性。
Infect Genet Evol. 2010 Jan;10(1):137-45. doi: 10.1016/j.meegid.2009.10.003. Epub 2009 Oct 14.
8
Dual-function antibodies to Yersinia pestis LcrV required for pulmonary clearance of plague.鼠疫肺部清除所需的针对鼠疫耶尔森菌LcrV的双功能抗体。
Clin Vaccine Immunol. 2009 Dec;16(12):1720-7. doi: 10.1128/CVI.00333-09. Epub 2009 Oct 14.
9
Mechanisms of major histocompatibility complex class II-restricted processing and presentation of the V antigen of Yersinia pestis.鼠疫耶尔森氏菌V抗原的主要组织相容性复合体II类限制加工与呈递机制
Immunology. 2006 Nov;119(3):385-92. doi: 10.1111/j.1365-2567.2006.02447.x. Epub 2006 Aug 18.
10
LcrV plague vaccine with altered immunomodulatory properties.具有改变免疫调节特性的LcrV鼠疫疫苗。
Infect Immun. 2005 Aug;73(8):5152-9. doi: 10.1128/IAI.73.8.5152-5159.2005.

本文引用的文献

1
BIOSYNTHESIS AND PURIFICATION OF V AND W ANTIGEN IN PASTEURELLA PESTIS.鼠疫耶尔森氏菌中V抗原和W抗原的生物合成与纯化
J Immunol. 1963 Aug;91:179-84. doi: 10.21236/ad0299868.
2
The effects of loss of different virulence determinants on the virulence and immunogenicity of strains of Pasteurella pestis.不同毒力决定因素缺失对鼠疫耶尔森氏菌菌株毒力和免疫原性的影响。
Br J Exp Pathol. 1958 Jun;39(3):278-91.
3
Virulence of Pasteurella pestis.鼠疫耶尔森菌的毒力
Nature. 1957 Jun 15;179(4572):1246-7. doi: 10.1038/1791246a0.
4
Protection against experimental bubonic and pneumonic plague by a recombinant capsular F1-V antigen fusion protein vaccine.
Vaccine. 1998 Jul;16(11-12):1131-7. doi: 10.1016/s0264-410x(98)80110-2.
5
Resistance to lipopolysaccharide mediated by the Yersinia pestis V antigen-polyhistidine fusion peptide: amplification of interleukin-10.鼠疫耶尔森氏菌V抗原-多组氨酸融合肽介导的对脂多糖的抗性:白细胞介素-10的扩增
Infect Immun. 1997 Apr;65(4):1196-203. doi: 10.1128/iai.65.4.1196-1203.1997.
6
Passive immunity to infection with Yersinia spp. mediated by anti-recombinant V antigen is dependent on polymorphism of V antigen.由抗重组V抗原介导的对耶尔森菌属感染的被动免疫取决于V抗原的多态性。
Infect Immun. 1997 Feb;65(2):446-51. doi: 10.1128/iai.65.2.446-451.1997.
7
V antigen-polyhistidine fusion peptide: binding to LcrH and active immunity against plague.V抗原-多聚组氨酸融合肽:与LcrH结合及对鼠疫的主动免疫
Infect Immun. 1996 Oct;64(10):4313-8. doi: 10.1128/iai.64.10.4313-4318.1996.
8
Recombinant V antigen protects mice against pneumonic and bubonic plague caused by F1-capsule-positive and -negative strains of Yersinia pestis.重组V抗原可保护小鼠免受由鼠疫耶尔森氏菌F1荚膜阳性和阴性菌株引起的肺鼠疫和腺鼠疫。
Infect Immun. 1996 Nov;64(11):4580-5. doi: 10.1128/iai.64.11.4580-4585.1996.
9
A new improved sub-unit vaccine for plague: the basis of protection.
FEMS Immunol Med Microbiol. 1995 Dec;12(3-4):223-30. doi: 10.1111/j.1574-695X.1995.tb00196.x.
10
Ability of synthetic peptides representing epitopes of outer membrane protein F of Pseudomonas aeruginosa to afford protection against P. aeruginosa infection in a murine acute pneumonia model.代表铜绿假单胞菌外膜蛋白F表位的合成肽在小鼠急性肺炎模型中抵御铜绿假单胞菌感染的能力。
Vaccine. 1995 Dec;13(18):1750-3. doi: 10.1016/0264-410x(95)00166-x.